In-hospital outcomes of catheter-directed thrombolysis versus anticoagulation in cancer patients with proximal deep venous thrombosis.

Published on Jul 1, 2020in Journal of vascular surgery. Venous and lymphatic disorders3.137
· DOI :10.1016/J.JVSV.2019.10.014
Yevgeniy Brailovsky5
Estimated H-index: 5
(Loyola University Medical Center),
Ho-Man Yeung3
Estimated H-index: 3
(TU: Temple University)
+ 3 AuthorsRiyaz Bashir15
Estimated H-index: 15
(TU: Temple University)
Abstract Objective The objective of this study was to determine the rate of complications of catheter-directed thrombolysis (CDT) in cancer patients with deep venous thrombosis (DVT) compared with anticoagulation therapy alone. Methods This observational study used the National Inpatient Sample database to screen for any cancer patients who were admitted with a principal discharge diagnosis of proximal lower extremity or caval DVT between January 2005 and December 2013. Patients treated with CDT plus anticoagulation were compared with those treated with anticoagulation alone using propensity score matching for comorbidities and demographic characteristics. The primary end point was in-hospital mortality. Secondary end points were acute intracranial hemorrhage, inferior vena cava filter placement, acute renal failure, blood transfusion rates, length of stay, and hospital charges. Results We identified 31,124 cancer patients with lower extremity proximal or caval DVT, and 1290 (4%) patients were treated with CDT. Comparative outcomes as assessed in the two matched groups of 1297 patients showed that there was no significant difference in in-hospital mortality of patients undergoing CDT plus anticoagulation compared with those treated with anticoagulation alone (2.6% vs 1.9%; P = .23). However, CDT was associated with increased risk of intracranial hemorrhage (1.3% vs 0.4%; P = .017), greater blood transfusion rates (18.6% vs 13.1 %; P  Conclusions There was no significant difference in in-hospital mortality of cancer patients who underwent CDT plus anticoagulation compared with anticoagulation alone. CDT was associated with increased in-hospital morbidity and resource utilization compared with anticoagulation alone. Further studies are needed to examine the effect of CDT on the development of PTS in this population.
#1Michael B. Streiff (Johns Hopkins University)H-Index: 58
#2Bjorn Holmstrom (USF: University of South Florida)H-Index: 3
Last. Anita M. Engh (National Comprehensive Cancer Network)H-Index: 12
view all 32 authors...
: Venous thromboembolism (VTE) is common in patients with cancer and increases morbidity and mortality. VTE prevention and treatment are more complex in patients with cancer. The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of VTE in adult patients diagnosed with cancer or in whom cancer is clinically suspected. These NCCN Guidelines Insights explain recent changes in anticoagulants recommended for the treatment of cancer-ass...
99 CitationsSource
#1Victor F. Tapson (Cedars-Sinai Medical Center)H-Index: 94
#2Keith M. SterlingH-Index: 14
Last. Samuel Z. Goldhaber (Brigham and Women's Hospital)H-Index: 132
view all 19 authors...
Abstract Objectives The aim of this study was to determine the lowest optimal tissue plasminogen activator (tPA) dose and delivery duration using ultrasound-facilitated catheter-directed thrombolysis (USCDT) for the treatment of acute intermediate-risk (submassive) pulmonary embolism. Background Previous trials of USCDT used tPA over 12 to 24 h at doses of 20 to 24 mg for acute pulmonary embolism. Methods Hemodynamically stable adults with acute intermediate-risk pulmonary embolism documented by...
120 CitationsSource
#1Suresh Vedantham (WashU: Washington University in St. Louis)H-Index: 37
#2Samuel Z. Goldhaber (Harvard University)H-Index: 132
Last. Clive Kearon (McMaster University)H-Index: 91
view all 30 authors...
BackgroundThe post-thrombotic syndrome frequently develops in patients with proximal deep-vein thrombosis despite treatment with anticoagulant therapy. Pharmacomechanical catheter-directed thrombolysis (hereafter “pharmacomechanical thrombolysis”) rapidly removes thrombus and is hypothesized to reduce the risk of the post-thrombotic syndrome. MethodsWe randomly assigned 692 patients with acute proximal deep-vein thrombosis to receive either anticoagulation alone (control group) or anticoagulatio...
305 CitationsSource
#1Resmi A. Charalel (WashU: Washington University in St. Louis)H-Index: 9
#2Suresh Vedantham (WashU: Washington University in St. Louis)H-Index: 37
The presence of cancer increases the risk of deep vein thrombosis (DVT), DVT recurrence, and treatment-related bleeding, and therefore offers distinctive clinical considerations when planning treatment. Anticoagulation with a low-molecular-weight heparin is the preferred initial and long-term therapy in cancer patients. Inferior vena cava filters may be used judiciously for patients with cancer-related DVT who have contraindications to anticoagulation or who exhibit breakthrough pulmonary emboli...
7 CitationsSource
#1Immad Sadiq (Hartford Hospital)H-Index: 4
#2Samuel Z. Goldhaber (Brigham and Women's Hospital)H-Index: 132
Last. Gregory Piazza (Brigham and Women's Hospital)H-Index: 40
view all 4 authors...
Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis minimizes the risk of intracranial bleeding compared with systemic full-dose fibrinolytic therapy for pulmonary embolism (PE). However, major bleeding is nevertheless a potential complication. We analyzed the 150-patient SEATTLE II trial of submassive and massive PE patients to describe those who suffered major bleeding events following ultrasound-facilitated, catheter-directed, low-dose fibrinolysis and to identify risk factors fo...
22 CitationsSource
#1L. Watson (CCC: Cameron International)H-Index: 15
#2Cathryn Broderick (Edin.: University of Edinburgh)H-Index: 3
Last. Matthew P. Armon (NNUH: Norfolk and Norwich University Hospital)H-Index: 9
view all 3 authors...
Background Standard treatment for deep vein thrombosis aims to reduce immediate complications. Use of thrombolysis or clot dissolving drugs could reduce the long-term complications of post-thrombotic syndrome (PTS) including pain, swelling, skin discolouration, or venous ulceration in the affected leg. This is the third update of a review first published in 2004. Objectives To assess the effects of thrombolytic therapy and anticoagulation compared to anticoagulation alone for the management of p...
246 CitationsSource
#1Susan R. Kahn (McGill University)H-Index: 84
#2jean Philippe Galanaud (University of Montpellier)H-Index: 1
Last. Jeffrey S. Ginsberg (McMaster University)H-Index: 113
view all 4 authors...
The post-thrombotic syndrome (PTS) is a frequent, potentially disabling complication of deep vein thrombosis (DVT) that reduces quality of life and is costly. Clinical manifestations include symptoms and signs such as leg pain and heaviness, edema, redness, telangiectasia, new varicose veins, hyperpigmentation, skin thickening and in severe cases, leg ulcers. The best way to prevent PTS is to prevent DVT with pharmacologic or mechanical thromboprophylaxis used in high risk patients and settings....
86 CitationsSource
#1William T. Kuo (Stanford University)H-Index: 28
#2Arjun Banerjee (Stanford University)H-Index: 5
Last. Miguel Ángel de Gregorio (University of Zaragoza)H-Index: 20
view all 12 authors...
BACKGROUND Systemic thrombolysis for acute pulmonary embolism (PE) carries up to a 20% risk of major bleeding, including a 2% to 5% risk of hemorrhagic stroke. We evaluated the safety and effectiveness of catheter-directed therapy (CDT) as an alternative treatment of acute PE. METHODS One hundred one consecutive patients receiving CDT for acute PE were prospectively enrolled in a multicenter registry. Massive PE (n = 28) and submassive PE (n = 73) were treated with immediate catheter-directed me...
235 CitationsSource
#1Gregory PiazzaH-Index: 40
#2Benjamin Hohlfelder (Brigham and Women's Hospital)H-Index: 8
Last. Seattle Ii InvestigatorsH-Index: 1
view all 28 authors...
Abstract Objectives This study conducted a prospective, single-arm, multicenter trial to evaluate the safety and efficacy of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis, using the EkoSonic Endovascular System (EKOS, Bothell, Washington). Background Systemic fibrinolysis for acute pulmonary embolism (PE) reduces cardiovascular collapse but causes hemorrhagic stroke at a rate exceeding 2%. Methods Eligible patients had a proximal PE and a right ventricular (RV)-to-left ventric...
384 CitationsSource
#1Nils KucherH-Index: 44
#2Peter BoekstegersH-Index: 56
Last. Iris BaumgartnerH-Index: 59
view all 19 authors...
Background—In patients with acute pulmonary embolism, systemic thrombolysis improves right ventricular (RV) dilatation, is associated with major bleeding, and is withheld in many patients at risk. This multicenter randomized, controlled trial investigated whether ultrasound-assisted catheter-directed thrombolysis (USAT) is superior to anticoagulation alone in the reversal of RV dilatation in intermediate-risk patients. Methods and Results—Fifty-nine patients (63±14 years) with acute main or lowe...
484 CitationsSource
Cited By3
#1Wei Xiong (SJTU: Shanghai Jiao Tong University)
Patients with cancer are prone to develop venous thromboembolism (VTE) that is the second leading cause of mortality among them. Cancer patients with VTE may encounter higher rates of VTE recurrence and bleeding complications than patients without cancer. Treatment of established VTE is often complex in patients with cancer. Treatment of cancer-associated VTE basically comprises initial treatment, long-term treatment, treatment within 6 months, treatment beyond 6 months, treatment of recurrent V...
#1Xin Li (Cleveland Clinic)H-Index: 3
#2Sasan Partovi (Cleveland Clinic)H-Index: 25
Last. Suresh Vedantham (WashU: Washington University in St. Louis)H-Index: 37
view all 6 authors...
Gastrointestinal malignancy encompasses a wide range of disease processes. Its incidence and mortality rate rank among the highest of all cancers. Venous thromboembolic disease is a common complication of gastrointestinal malignancy. Anticoagulation remains the first-line therapy. However, for patients who cannot tolerate or have failed anticoagulation, inferior vena cava (IVC) filter placement may be an option. Furthermore, to improve symptom resolution and reduce the severity of postthrombotic...
1 CitationsSource